Innovative CNS Therapeutics ReNetX Bio is focused on developing first-in-class therapies targeting central nervous system injuries and conditions such as spinal cord injury, glaucoma, and traumatic brain injury, which presents opportunities for partnerships with medical device and biotech firms targeting neurological health.
R&D Progress and Potential Approaching Phase 2 trials with its lead candidate AXER-204 indicates significant scientific validation and growth potential that could attract strategic investors, licensing partners, or collaborations for expanded testing and commercialization.
Funding and Growth Capacity With $2.8 million in funding and early-stage revenue, ReNetX is positioned for further capital infusion and partnership opportunities, especially from investors interested in biotech innovations within neuroregeneration.
Recognition and Leadership The CEO Erika Smith has received awards for entrepreneurial innovation, highlighting strong leadership that can support strategic outreach, investor confidence, and partnership opportunities with organizations seeking visionary biotech collaborations.
Technological Development Potential ReNetX’s utilization of diverse digital tools and its focus on cutting-edge therapeutics present opportunities for tech partnerships in digital health, data analytics, and platform development to enhance research and clinical trial efficiency.
$100M$250M
$25M$50M
$250M$500M
$1M$10M
$250M$500M
$1M$10M
$1M$10M
$25M$50M
$1MReNetX Bio uses 8 technology products and services including Snowplow, Weebly, Google Fonts API, and more. Explore ReNetX Bio's tech stack below.
| ReNetX Bio Email Formats | Percentage |
| FLast@renetx.com | 50% |
| FLast@renetx.com | 50% |
Biotechnology ResearchUnited States2-10 Employees
Our mission is to provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), glaucoma, and traumatic brain injury. Our treatment, AXER-204, hopes to rebuild connections between healthy and damaged neurons through the blocking of receptors that naturally inhibit axonal growth. We are currently approaching Phase 2 of testing.
Company Overview
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com